Navigation Links
Viral Enzyme Recruited in Fight Against Ear Infection

St. Jude Study Success in Using Virus Enzyme to Treat Mouse Model of Acute Otitis Media Suggests that Nasal Spray Could Be Used to Prevent Both Ear Infection and Pneumonia in People with Influenza

MEMPHIS, Tenn., March 22, 2007 /PRNewswire/ -- Parents might one day give their children a weekly treatment with a nasal spray of virus enzymes to prevent them from getting a severe middle ear infection, based on results of a study done in mice by investigators from St. Jude Children's Research Hospital and The Rockefeller University, in New York. Such a treatment would avoid the use of antibiotics, thus eliminating the problem of antibiotic resistance. A report on this study appears in the March issue of the online journal "PLoS Pathogens."

Middle ear infection, also called acute otitis media, is an inflammation of the middle ear space. About half of all children carry Streptococcus pneumoniae, the bacteria that cause acute otitis media. These bacteria migrate from the nose and throat to the middle ear after an initial influenza virus infection paves the way.

The investigators based their treatment on the ability of viruses called phages to break out of bacteria they infect by using a special enzyme to destroy the cell walls.

The success of the new treatment, which uses a phage enzyme called lysin to kill S. pneumonia, suggests that the strategy could significantly reduce the incidence of acute otitis media in the United States. More than 24 million cases are now diagnosed each year, despite the use of vaccines against S. pneumoniae.

"Lysin also appears to hold promise for preventing the secondary pneumonia caused when a person infected with S. pneumoniae is subsequently infected with the influenza virus, said Jonathan McCullers, M.D., associate member in the Infectious Diseases department at St. Jude. McCullers is first author of the "PLoS" paper.

The investigators demonstrated tha t lysin can eliminate these bacteria from the ear using mice developed at St. Jude that represented the first such model in which acute otitis media develops in a similar way that it develops the disease in children. The mice were treated by purified lysin that was prepared in the laboratory of Vincent A. Fischetti, Ph.D., a professor and co- head of the Laboratory of Bacterial Pathogenesis and Immunology at The Rockefeller University. He was assisted by Jutta M. Loeffler, postdoctoral associate. Fischetti is senior author of the "PLoS" paper.

"The nasal spray may eventually be used weekly during flu season to keep a person free of Streptococcus pneumoniae or after infection with the flu virus," said Fischetti. "This might truly be a case in which an ounce of prevention would be worth a pound of cure."

Other St. Jude authors of this paper include Asa Karlstrom and Amy R. Iverson (St. Jude).

This work was supported in part by the United States Public Health Service and ALSAC.

St. Jude Children's Research Hospital

St. Jude Children's Research Hospital is internationally recognized for its pioneering work in finding cures and saving children with cancer and other catastrophic diseases. Founded by late entertainer Danny Thomas and based in Memphis, Tenn., St. Jude freely shares its discoveries with scientific and medical communities around the world. No family ever pays for treatments not covered by insurance, and families without insurance are never asked to pay. St. Jude is financially supported by ALSAC, its fundraising organization. For more information, please visit www.stjude.org.

CONTACT: Carrie Strehlau, St. Jude Public Relations, +1-901-495-2295,; Summer Freeman, St. Jude Public Relations,+1-901-495-3061, , or Marc Kusinitz, Ph.D.,Scientific Communications, +1-901-495-5020, carrie.strehlau@stjude.org summer.freeman@stjude.org marc.kusinitz@stjude.org

Web site: http://www.stjude.org/

Terms and conditions of use apply
Copyright © 2007 PR Newswire Association LLC. All rights reserved.
A United Business Media Company


'"/>




Related medicine technology :

1. Advanced Viral Research Corp. Announces Positive Preliminary Findings from Ongoing Phase II Dermatological Study
2. Sirion Therapeutics Receives Orphan Drug Designation for Ophthalmic Drug to Treat Viral Eye Infection
3. Baraclude (Entecavir) Treatment Demonstrated Greater Viral Load Reduction Compared to Adefovir at 48 Weeks in Study of Antiviral-Naive Chronic Hepatitis B E-Antigen Positive Patients
4. Afid Therapeutics Obtains Positive Evaluation of its Triple Mode Viral Sequestration Agents
5. NIEHS Researchers Identify Enzyme Critical in DNA Replication
6. AGI Dermatics Data Shows the 8 Oxo-Guanine Repair Enzyme OGG1 Encapsulated in Liposomes, Reduces MMP-1 and TNF-alpha in UV Irradiated Skin Cells
7. Study Presented at the ACC Shows Inflammatory Enzyme Lp-PLA2 Predicts Heart Disease Risk in Metabolic Syndrome Patients
8. MediGene Announces Cancer-Fighting Virus Shows Promise in Early Clinical Trial
9. New Drugs in Multinational Study Show Promise in Fighting Drug-Resistant HIV
10. Neuroblastoma Expert Reviews Progress and Challenges in Fighting Difficult Pediatric Cancer
11. Alzheimers Drug Shows Promise in Fighting Cancer
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/23/2016)... 2016  Experian Health, the healthcare industry ... patient payment and care experience, today announced ... and services that will enhance the breadth ... These award-winning solutions will enable healthcare professionals ... in an ever-changing environment and redefine front-office ...
(Date:6/23/2016)... 2016  The National Pharmaceutical Council (NPC) today ... policy research organization as its newest member.  ... vice president and chief scientific officer, Mallinckrodt Pharmaceuticals, ... NPC Board of Directors. ... joined us in support of our efforts to ...
(Date:6/23/2016)... , June 23, 2016  Delcath Systems, Inc. (NASDAQ: ... device company focused on treatment of primary and metastatic ... European patient education - www.againsttheodds.eu - has ... Digital Health Awards. The website ... European patients and their families who are coping with ...
Breaking Medicine Technology:
(Date:6/25/2016)... ... June 25, 2016 , ... As a lifelong Southern Californian, Dr. Omkar Marathe ... from the David Geffen School of Medicine at UCLA. He trained in Internal Medicine ... his fellowship in hematology/oncology at the UCLA-Olive View-Cedars Sinai program where he had the ...
(Date:6/24/2016)... (PRWEB) , ... June 24, 2016 , ... Those who ... with these feelings, many turn to unhealthy avenues, such as drug or alcohol abuse, ... Marne, Michigan, has released tools for healthy coping following a traumatic event. , Trauma ...
(Date:6/24/2016)... Francisco, CA (PRWEB) , ... June 24, 2016 ... ... CitiDent, is now offering micro-osteoperforation for accelerated orthodontic treatment. Dr. Cheng has extensive ... self-ligating Damon brackets , AcceleDent, and accelerated osteogenic orthodontics. , Micro-osteoperforation ...
(Date:6/24/2016)... ... June 24, 2016 , ... The Haute Beauty Network, ... M. Weintraub as a prominent plastic surgeon and the network’s newest partner. ... the most handsome men, look naturally attractive. Plastic surgery should be invisible.” He ...
(Date:6/24/2016)... ... 2016 , ... Today, MTI-GlobalStem, a provider of optimized transfection ... to transfect cells, announces its launch of the PluriQ™ G9™ Gene Editing System ... is a complete system for culturing and transfecting human pluripotent stem cells for ...
Breaking Medicine News(10 mins):